Formulation And Evaluation Of Antiepileptic Medicated Jelly

Abstract

This study focuses on the formulation and evaluation of Brivaracetam-loaded medicated jelly designed for pediatric patients to improve drug delivery. The formulation was optimized to ensure consistent drug content, with each jelly unit containing 25 mg of Brivaracetam, and a final drug load of 491 mg per Petri plate accounting for practical losses. The physical evaluation revealed favorable characteristics such as uniform appearance, soft texture, and minimal stickiness, with slight grittiness in a few batches that may impact patient acceptability. The pH of the formulations (6.45–7.12) was compatible with oral mucosa. Syneresis studies showed minor syneresis in some batches, indicating stability and potential for optimization. Increased viscosity was observed with higher concentrations of gelatin, sodium alginate, and pectin, improving texture and drug release control. In-vitro dissolution studies will provide insights into the drug release kinetics, further validating the formulation’s potential for controlled, effective drug delivery. This research lays the foundation for optimizing and scaling Brivaracetam-loaded medicated jelly formulations to meet the needs of pediatric patients.